News - Onyx Pharmaceuticals, Kyprolis

Filter

Popular Filters

US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma

15-05-2013

US and European hematological oncologists surveyed by health care advisory firm Decision Resources indicate…

carfilzomibEuropeKyprolisMarkets & MarketingNorth AmericaOncologyOno PharmaceuticalOnyx PharmaceuticalsPharmaceuticalpomalidomide

Onyx soars as FDA approves Kyprolis for multiple myeloma

23-07-2012

Shares of US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) leapt 11.7% to $76.38 on Friday, after…

BiotechnologyKyprolisNorth AmericaOncologyOnyx PharmaceuticalsRegulation

Batch of mixed opinions from FDA advisory panels

21-06-2012

Advisory panels of the US Food and Drug Administration meeting yesterday came back with a mixture of…

carfilzomibKyprolisMerck & CoNorth AmericaOncologyOnyx PharmaceuticalsPfizerPharmaceuticalPneumovaxPrevnarRegulationSanofisemuloparinVaccines

Back to top